Results 161 to 170 of about 285,474 (314)

Sotatercept in Pulmonary Langerhans Cell Histiocytosis‐Associated Pulmonary Hypertension: A Case Series and Systematic Review

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary Langerhans cell histiocytosis (PLCH) frequently complicated by pulmonary hypertension (PH), which markedly worsens prognosis. We retrospectively reviewed three institutional PLCH‐PH cases treated with off‐label Sotatercept added to background triple therapy and performed a systematic review of published PLCH‐PH reports (PubMed/Embase
Giorgi Chilingarashvili, Ruben Joseph Mylvaganam, Roberto J. Bernardo, Aimal Shah, Michael Cuttica, Tara Roberts, Nathaniel Marchetti, Parth Rali   +7 more
wiley   +1 more source

Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis. [PDF]

Front Pharmacol
Kuc RE, Paterson AL, Williams TL, Gelson WTH, Greasley PJ, Ambery P, Maguire JJ, Davenport AP.   +7 more
europepmc   +1 more source

Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis [PDF]

, 2010
Martin Reriani, Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, Geralyn M. Pumper, Rebecca E. Nelson, Ryan J. Lennon, Charanjit S. Rihal, Lilach O. Lerman, Amir Lerman   +9 more
openalex   +1 more source

Knowledge Gaps and Controversies on Cardiopulmonary Exercise Testing in the Assessment of Pulmonary Vascular Disease: An Official Statement of the Pulmonary Vascular Research Institute Exercise and Right Ventricular Function Task Force

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Exercise testing has long been essential for evaluating diagnosis, prognosis, and functional status in pulmonary hypertension (PH). Recent advances have clarified its role in defining reference values and prognostic markers. Nonetheless, substantial knowledge gaps persist regarding the implementation of invasive cardiopulmonary exercise ...
Aaron B. Waxman, Abraham Babu, Roberto Badagliacca, Eloara Ferreira, Patty George, Marco Guazzi, Luke Howard, Darlene Kim, Gabor Kovacs, Saad Kubba, David Langleben, Colm McCabe, Thais Menezes, Rudolf Oliveira, Stylianos Orfanos, Inderjit Singh, David Systrom, Ryan Tedford, Rebecca Vanderpool, Carmine Dario Vizza, Franz P. Rischard   +20 more
wiley   +1 more source

Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats

, 2003
Robert P. Ostrowski, Sławomir Januszewski, Zdzisława Kowalska, A Kapuściński   +3 more
openalex   +1 more source

MP44-13 EFFECTS OF THE RECEPTOR ANTAGONIST PICOTAMIDE ON ENDOTHELIN-1-, -2- AND -3-INDUCED CONTRACTIONS IN HUMAN PROSTATE SMOOTH MUSCLE [PDF]

, 2016
Alexander Tamalunas, Christian Gratzke, Frank Strittmatter, Raphaela Waidelich, Christian G. Stief, Martin Hennenberg   +5 more
openalex   +1 more source

Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units
Roela Sadushi‐Koliçi, Leila Alajbegovic, Vladimir Gojic, Nika Skoro‐Sajer, Ioana Campean, Inbal Shafran, Deddo Mörtl, Christian Gerges, Irene M. Lang   +8 more
wiley   +1 more source

Pharmacological Profile in vitro of A New Endothelin Receptor Antagonist, TAK-044.

, 1994
Yumiko Awane, Keiji Kusumoto, Kazuki Kubo, Akira Kawata, Takashi Kikuchi, Mitsyhiro Wakimasu, Toshifumi Watanabe, Masahiko Fujino   +7 more
openalex   +1 more source

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [PDF]

, 2017
Nazzareno Galiè, Pavel Jansa, Tomás Pulido, Richard N. Channick, Marion Delcroix, Hossein Ardeschir Ghofrani, Franck‐Olivier Le Brun, Sanjay Mehta, Loı̈c Perchenet, Lewis J. Rubin, B.K.S. Sastry, Gérald Simonneau, Olivier Sitbon, Rogério Souza, Adam Torbicki   +14 more
openalex   +1 more source

Methamphetamine‐Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Methamphetamine‐associated pulmonary arterial hypertension (Meth‐PAH) is an increasingly prevalent but understudied subtype of Group 1 pulmonary arterial hypertension (PAH). While most prevalent in the Western United States, its reach continues to expand with the evolving global methamphetamine epidemic.
Namita Sood, Jonika Weerasekare, Iryna Zhyvylo, Elena A. Goncharova, Teresa De Marco   +4 more
wiley   +1 more source